New York, Feb 21, 2026, 14:49 EST — Market closed.
- UnitedHealth shares wrapped up Friday at $290, just 0.02% higher, after a session that saw plenty of back-and-forth in the stock.
- Fresh federal figures indicate that Medicare Advantage enrollment, which has been a major source of profit for large insurers, is set to see slower growth heading into 2026.
- Next week, eyes turn to the Feb. 25 CMS comment deadline for proposed changes to 2027 Medicare Advantage payments.
UnitedHealth Group Incorporated ended Friday at $290.00, ticking up just 0.07 from the previous session. Shares hit a low of $285.55 during the day, with roughly 7.0 million traded.
U.S. markets are closed for the weekend, leaving traders focused on what could sway the stock ahead of the New York Stock Exchange’s Monday open—namely, Medicare Advantage policy developments and the first hints at whether major insurers are maintaining enrollment following plan withdrawals and trimmed benefits.
This hits UnitedHealth, whose UnitedHealthcare division ranks among the Medicare Advantage heavyweights. Medicare Advantage, the privately managed offshoot of standard Medicare, has been the sector’s go-to for growth and margin support whenever commercial insurance turns unpredictable.
Medicare Advantage enrollment reached just under 35.5 million in early February, compared with roughly 34.4 million a year ago, new federal data showed, according to CMS numbers cited by Fierce Healthcare. UnitedHealthcare and CVS Health’s Aetna moved to scale back in some regions and trimmed benefits amid higher medical spending and utilization, Fierce reported, while Humana picked up more new members than it expected for the annual sign-up period.
“The most dire predictions didn’t come to pass. The market remains fairly robust,” said Meredith Freed, senior policy manager at KFF’s Medicare policy program. She noted, though, that growth isn’t as rapid as before. MarketWatch
But 2027 is where the real uncertainty lingers. CMS is projecting just a 0.09% net average payment boost for Medicare Advantage plans that year, according to its proposal. Comments are on the clock, due by Feb. 25, with the final word on rates expected by April 6. The agency is also eyeing revisions to risk adjustment, taking some diagnoses out of the formula used to determine plan payments.
Health insurers largely slipped Friday despite the broader indexes climbing. UnitedHealth stood out, barely moving with a 0.02% uptick. The S&P 500 picked up 0.69%, and the Dow added 0.47%. CVS ended off 0.81%, while Elevance Health dropped 1.51%, according to MarketWatch data.
UnitedHealth’s shares have struggled to recover since late January, when the company flagged a revenue drop for 2026 and the sector stumbled following the government’s almost unchanged 2027 Medicare Advantage payment draft. “Investors hoping for a quick turnaround may have to wait longer than hoped,” Morningstar analyst Julie Utterback said back then. Reuters
Much of the debate centers on “risk adjustment”—that’s the government’s formula for tweaking insurer payments up or down, depending on the severity of members’ illnesses as identified by diagnosis codes. Even minor tweaks in which codes qualify can ripple through payments for millions.
But here’s the hitch: if CMS goes ahead with the 2027 proposal—keeping headline rates steady and clamping down on diagnosis coding—insurers’ wiggle room for funding extra perks or swallowing higher medical costs shrinks. Hiking premiums and co-pays gets harder to avoid. And if utilization jumps again, the squeeze tightens, particularly if firms opt to exit more counties.
UnitedHealth faces a stretch where the spotlight drifts from splashy headlines to the quieter churn—comment letters, Beltway chatter tied to Medicare Advantage, and whatever signals CMS drops about tweaking its stance on risk-model changes.
Mark Feb. 25 for comments on the 2027 Medicare Advantage proposal, and circle April 6 as the date for the final CMS rate announcement—both could move the entire managed-care group.
